Roche v. Biosite
This article was originally published in The Gray Sheet
Executive Summary
San Diego manufacturer Biosite believes patent infringement allegations filed Nov. 9 by Roche in Indianapolis federal court are without merit. The suit references two Roche U.S. patents covering a biosensing meter and a device used for separating plasma or serum from whole blood. Biosite markets the Triage line of drugs-of-abuse assays, cardiac marker test kits and B-type natriuretic peptide (BNP) point-of-care hormone diagnostic tests...
You may also be interested in...
Biosite sues Roche
San Diego firm files complaint in California district court alleging Roche Diagnostics is infringing on two patents related to methods for measuring cardiac troponin forms, according to a Nov. 30 release. The filing marks the second suit Biosite has brought against Roche in recent months. On Nov. 9, the firm brought patent infringement allegations in Indianapolis federal court regarding its biosensing meter and a device used for separating plasma or serum from whole blood (1"The Gray Sheet" Nov. 22, 2004, In Brief)...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.